Phase 1 Clinical Trial of Human Hookworm Vaccine Successfully Completed

WASHINGTON, D.C. — September 3, 2014 — The Sabin Vaccine Institute (Sabin) today announced that its product development partnership (Sabin PDP) successfully completed a Phase 1 clinical trial in Brazil of Na-GST-1/Alhydrogel®, a vaccine candidate for human hookworm, one of the most pervasive neglected tropical diseases (NTDs) affecting the world’s poor. The Sabin PDP is based at Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine in Houston, Texas.

Last week, researchers, academics, doctors and advocates from all over the world gathered in Mexico City, Mexico at the 13th International Congress of Parasitology (ICOPA). Sabin Vaccine Institute (Sabin) President Dr.

The accomplishments and work of Sabin and its three major programs — Vaccine Advocacy & Education, the Sabin Product Development Partnership (Sabin PDP) and the Global Network for Neglected Tropical Diseases (Global Network) — are highlighted in our 2013 Annual Report.

With the Millennium Development Goals (MDGs) sunsetting next year and the post-2015 development agenda and Sustainable Development Goals (SDGs) shaping up, countries and development partners are busy assessing progress and proposing plans to overcome key impediments.

Pages

Subscribe to RSS - Sabin Vaccine Development